CY1124708T1 - Φαρμακολογικως δραστικα αλικυκλικα υποκατεστημενα παραγωγα πυραζολο[1,5-a] πυριμιδινης - Google Patents

Φαρμακολογικως δραστικα αλικυκλικα υποκατεστημενα παραγωγα πυραζολο[1,5-a] πυριμιδινης

Info

Publication number
CY1124708T1
CY1124708T1 CY20211100964T CY211100964T CY1124708T1 CY 1124708 T1 CY1124708 T1 CY 1124708T1 CY 20211100964 T CY20211100964 T CY 20211100964T CY 211100964 T CY211100964 T CY 211100964T CY 1124708 T1 CY1124708 T1 CY 1124708T1
Authority
CY
Cyprus
Prior art keywords
pyrimidine derivatives
compounds
pharmaceutically active
relates
substituted pyrazolo
Prior art date
Application number
CY20211100964T
Other languages
Greek (el)
English (en)
Inventor
István BORZA
Viktor ROMÁN
János ÉLES
Zsuzsa HADADY
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of CY1124708T1 publication Critical patent/CY1124708T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20211100964T 2017-03-13 2021-11-08 Φαρμακολογικως δραστικα αλικυκλικα υποκατεστημενα παραγωγα πυραζολο[1,5-a] πυριμιδινης CY1124708T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1700108A HU231058B1 (hu) 2017-03-13 2017-03-13 Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
PCT/IB2018/051599 WO2018167630A1 (en) 2017-03-13 2018-03-12 PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
CY1124708T1 true CY1124708T1 (el) 2022-07-22

Family

ID=89992389

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100964T CY1124708T1 (el) 2017-03-13 2021-11-08 Φαρμακολογικως δραστικα αλικυκλικα υποκατεστημενα παραγωγα πυραζολο[1,5-a] πυριμιδινης

Country Status (32)

Country Link
US (1) US11026946B2 (enExample)
EP (1) EP3596080B1 (enExample)
JP (1) JP7153662B2 (enExample)
KR (1) KR20190127779A (enExample)
CN (1) CN110431142A (enExample)
AR (1) AR111176A1 (enExample)
AU (1) AU2018235266B2 (enExample)
BR (1) BR112019018843A2 (enExample)
CA (1) CA3056185A1 (enExample)
CL (1) CL2019002601A1 (enExample)
CO (1) CO2019010120A2 (enExample)
CY (1) CY1124708T1 (enExample)
DK (1) DK3596080T3 (enExample)
EA (1) EA038756B1 (enExample)
EC (1) ECSP19072975A (enExample)
ES (1) ES2893824T3 (enExample)
GE (1) GEP20217256B (enExample)
HR (1) HRP20211850T1 (enExample)
HU (2) HU231058B1 (enExample)
IL (1) IL268923A (enExample)
LT (1) LT3596080T (enExample)
MX (1) MX2019011000A (enExample)
MY (1) MY195262A (enExample)
PE (1) PE20191646A1 (enExample)
PH (1) PH12019501968A1 (enExample)
PL (1) PL3596080T3 (enExample)
PT (1) PT3596080T (enExample)
RS (1) RS62533B1 (enExample)
SG (1) SG11201907864YA (enExample)
SI (1) SI3596080T1 (enExample)
UA (1) UA124783C2 (enExample)
WO (1) WO2018167630A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3595665T (pt) 2017-03-13 2024-11-21 Lundbeck La Jolla Research Center Inc Inibidores duplos de magl e faah
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
WO2021239558A1 (en) 2020-05-27 2021-12-02 Esteve Pharmaceuticals, S.A. Pyrazolo[1,5-a]pyrimidine derivatives having multimodal activity against pain
TWI907472B (zh) 2020-08-05 2025-12-11 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔1,5-a〕嘧啶衍生物
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN115872095A (zh) * 2022-11-28 2023-03-31 南通三鑫车灯配件有限公司 一种汽车车灯反光罩的生产线流转装置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0508310A (pt) 2004-03-02 2007-07-24 Hoffmann La Roche derivados de 4-(sulfanil-pirimidin-4-ilmetil)-morfolina e compostos relacionados como ligandos do receptor gaba, para o tratamento de ansiedade, depressão e epilepsia
GB0512844D0 (en) 2005-06-23 2005-08-03 Novartis Ag Organic compounds
KR100753017B1 (ko) * 2006-05-25 2007-08-30 한국화학연구원 7-(3,4-디알콕시페닐)-피라졸로[1,5-a]피리미딘 화합물을포함하는 관절염, 아토피 피부염, 백혈병을 포함한 암 및알쯔하이머, 우울증 또는 기억력 감소 등의 뇌질환의 치료및 예방을 위한 약제학적 조성물
WO2009123986A1 (en) * 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
TWI648281B (zh) 2013-10-17 2019-01-21 日商安斯泰來製藥股份有限公司 含硫二環式化合物
WO2016169995A1 (en) * 2015-04-20 2016-10-27 AbbVie Deutschland GmbH & Co. KG Substituted pyrazolopyrimidines and method of use
JP2018199623A (ja) * 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok

Also Published As

Publication number Publication date
PE20191646A1 (es) 2019-11-07
HUP1700108A2 (en) 2018-09-28
US11026946B2 (en) 2021-06-08
IL268923A (en) 2019-10-31
AR111176A1 (es) 2019-06-12
BR112019018843A2 (pt) 2020-04-14
AU2018235266B2 (en) 2021-09-30
EP3596080B1 (en) 2021-09-01
ECSP19072975A (es) 2019-11-30
HRP20211850T1 (hr) 2022-03-04
GEP20217256B (en) 2021-05-25
JP2020510041A (ja) 2020-04-02
HUE056562T2 (hu) 2022-02-28
PL3596080T3 (pl) 2022-01-31
JP7153662B2 (ja) 2022-10-14
SG11201907864YA (en) 2019-09-27
RS62533B1 (sr) 2021-11-30
ES2893824T3 (es) 2022-02-10
AU2018235266A1 (en) 2019-10-17
CN110431142A (zh) 2019-11-08
MX2019011000A (es) 2019-10-17
CO2019010120A2 (es) 2019-10-09
UA124783C2 (uk) 2021-11-17
WO2018167630A1 (en) 2018-09-20
HU231058B1 (hu) 2020-04-28
US20200129515A1 (en) 2020-04-30
SI3596080T1 (sl) 2022-01-31
EP3596080A1 (en) 2020-01-22
DK3596080T3 (da) 2021-11-15
EA201992127A1 (ru) 2020-02-06
CL2019002601A1 (es) 2020-01-24
KR20190127779A (ko) 2019-11-13
MY195262A (en) 2023-01-11
LT3596080T (lt) 2021-11-25
PT3596080T (pt) 2021-10-22
PH12019501968A1 (en) 2020-06-29
EA038756B1 (ru) 2021-10-14
CA3056185A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
EA201992127A1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
EA202091930A1 (ru) Макроциклы в качестве модуляторов муковисцидозного трансмембранного регулятора проводимости, их фармацевтические композиции, применение их для лечения муковисцидоза и способ их изготовления
UY39723A (es) Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2019013954A (es) Inhibidores covalentes de kras.
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
EA202090573A1 (ru) Составы нирапариба
CL2020002562A1 (es) (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
JP2013010792A5 (enExample)
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
CO2023001367A2 (es) Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterocíclicos farmacológicamente activos
EA201692300A1 (ru) Производные карбоксамида
CY1124301T1 (el) Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa
CY1123185T1 (el) Παραγωγα ινδολιου
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
EA201991128A1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
EA201990850A1 (ru) Модулятор муковисцидозного трансмембранного регулятора проводимости, фармацевтические композиции, способы лечения и способы получения модулятора
EA202091047A1 (ru) Пиридинкарбонильные производные и их терапевтические применения в качестве ингибиторов trpc6
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов